Lantern Pharma Inc. 8-K

What Happened

• Lantern Pharma Inc. announced (Regulation FD disclosure, Item 7.01) that on April 9, 2026 it conducted a live demonstration of withZeta.ai, its "multi-agentic AI co‑scientist" for rare cancer drug discovery, development, and clinical trial design. The company used a presentation during the demo and furnished that presentation as Exhibit 99.1 to the Form 8‑K filed April 10, 2026. A replay of the demonstration is available online.

Key Details

• Date of demonstration: April 9, 2026 (Form 8-K filed April 10, 2026).
• Exhibit furnished: Presentation used in the demo is filed as Exhibit 99.1 and incorporated by reference.
• Topics covered: withZeta.ai platform capabilities and commercial architecture, rare cancer market opportunity, competitive positioning, and the company’s near-term revenue strategy and growth roadmap.
• Replay available: company-provided recording of the demonstration (link included in the filing).

Why It Matters

• This disclosure signals Lantern is actively promoting and positioning withZeta.ai as a commercial platform addressing rare cancers, and the presentation outlines the company’s near-term revenue strategy and growth roadmap tied to that platform. For investors, the filed presentation and replay provide direct detail on Lantern’s AI platform focus, market opportunity, and how the company plans to commercialize those capabilities. The Regulation FD filing ensures the information was shared broadly and is part of the company’s public disclosure record.